Provider review
Good Girl Rx review
Received an FDA warning letter dated 2026-02-20 for "FDA-approved" marketing claims
Good Girl Rx, founded and wholly owned by reality-TV personality Savannah Chrisley since March 2025, prices compounded semaglutide injectable from $134/mo and ODT pills from $214/mo, with compounded tirzepatide injectable from $235/mo and ODT pills from $291/mo, all confirmed live. Independently confirmed via the FDA's own warning-letter index and corroborating news coverage: Good Girl, LLC dba GoodGirlRx received an FDA warning letter dated 2026-02-20, citing website language including "FDA-approved meds," "FDA-approved options," and "clinically proven GLP-1 results" as false or misleading for products that are actually unapproved compounded drugs. The company was given 15 business days to correct the violations and has since updated its site language and added disclaimers; the founder characterized it publicly as a wording issue, with no fines or disciplinary action reported. Its own legal entity, Good Girl, LLC dba GoodGirlRx, is confirmed live at a Nashville, TN address, though its compounding pharmacy is never named.
Straight talk: how we earn — some, not all, of these are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.
On this page
The verdict
Good Girl Rx's founder story is real and unusually well-documented for this category — Savannah Chrisley bought the company outright after an initial partnership, a fact independently confirmed across multiple outlets. But the single most important fact for this review is the FDA warning letter dated February 2026, independently confirmed via the agency's own index, citing marketing language that overstated FDA approval for products that don't have it. The company corrected the language within its 15-day window, and no penalty was issued — worth knowing both that the finding is real and that it was addressed, rather than treating it as either disqualifying or dismissible.
Good Girl Rx is not ranked on any of our boards. This is a standalone read of what the company publishes about itself — the providers we do rank in this category are on our semaglutide provider ranking. Nothing on this page is a performance claim — see the evidence review for what these compounds do and do not do.
Who it is for, and who it is not
A good fit if
- You want multiple formats (injectable, microdose, ODT pills) for both semaglutide and tirzepatide from one provider
- You've read the FDA warning letter and are satisfied the site has corrected the cited language
- You want brand-name options (Ozempic, Wegovy, Zepbound, Mounjaro) alongside compounded
Look elsewhere if
- You want a provider with a clean current regulatory record — this one has a February 2026 FDA warning letter
- You want a named compounding pharmacy — none is disclosed
- You're wary of a very new brand (founded 2025) with a short independent track record
What it actually costs
What they advertise
Compounded semaglutide injectable: from $134/mo, confirmed live on goodgirlrx.com.
What you actually pay, month to month
The $134 figure is for semaglutide only; tirzepatide injectable runs higher, from $235/mo, confirmed live. ODT pill formats and brand-name options are priced separately and higher still.
The commitment trap
The $134 headline is the semaglutide price only — tirzepatide, offered on the same site, starts at $235/mo instead.
Checked live on Good Girl Rx's own site at https://goodgirlrx.com in August 2026. Prices change without notice — confirm before you buy. Work out what a vial actually gives you with our peptide dose calculator.
What is included
The cheapest headline number in this category is often the one with the least attached to it. Here is what Good Girl Rx bundles in, and what it does not.
Clinician consult
Provider evaluation, confirmed live; a one-time video or phone…
consult is required in New Mexico, Kansas, West Virginia, Louisiana, and Mississippi due to state telehealth law.
Bloodwork / labs
Not addressed in the sources read.
Follow-ups and dose changes
Not addressed with a specific cadence in the sources read.
Human support
Not addressed with specifics in the sources read.
Injection supplies
Included in the medication price, confirmed live.
Shipping
Not addressed with specific terms in the sources read.
Pharmacy, labs and oversight
The pharmacy
Not named; described only as independent state-licensed compounding pharmacies, confirmed live.
Oversight
Provider evaluation, confirmed live; a one-time video or phone consult is required in New Mexico, Kansas, West Virginia, Louisiana, and Mississippi due to state telehealth law. Not addressed with a specific cadence in the sources read.
Compounded peptides are not FDA-approved products, and a 503A pharmacy compounds for a named patient while a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not. Our guide to verifying a certificate of analysis covers what to ask for.
Where you can get it
All 50 states, confirmed live, with additional consult requirements in New Mexico, Kansas, West Virginia, Louisiana, and Mississippi.
The honest cons
The part they would rather you skipped
Good Girl, LLC dba GoodGirlRx received an FDA warning letter dated 2026-02-20, independently confirmed via the FDA's own warning-letter index, citing site language including "FDA-approved meds" and "clinically proven GLP-1 results" as false or misleading for unapproved compounded products — corrected within the agency's 15-day window, with no fines or disciplinary action reported.
- FDA warning letter dated 2026-02-20 for "FDA-approved" and "clinically proven" marketing claims
- Compounding pharmacy never named
- Very new brand with a short independent track record
- Five states require an additional consult step due to state telehealth law
None of this is unique to Good Girl Rx — the whole category shares it. What we hold against a provider is the part it hides, and the ways vendors hide things are catalogued in our vendor red-flags guide.
How it compares
The providers we rank on our semaglutide provider ranking, in the order that board ranks them. Good Girl Rx is not among them: it is reviewed here, not ranked there, and we would rather show you the comparison than pretend the two are the same thing.
- BHBodybuilding Health+One of the deepest peptide catalogues here, and the loosest one
- Enhance MDWrites a flat-price-at-every-dose policy down — and charges near the top for it
- RxSpan MDOral tablet only, at a real $179 monthly rate
- Direct MedsThe plainest price mechanics on either board, from a company with an FDA warning letter
- Synergy RxPublishes a starting number, and nothing about what it commits you to
- Sprout HealthA $150 markdown the site never explains, and a semaglutide price quoted by the quarter
- Strut HealthInjection or troche, but $119 is the auto-refill price only
- MadeMedPrices are published — but there is no monthly option at all
7 more providers rank on our semaglutide provider ranking — see the full ranking. Every provider we review →
Read this before you buy
A provider comparison is half the decision. The other half is whether the compound does anything for you at all — and whether it is allowed where you compete. Growth-hormone secretagogues are banned in tested sport, year-round, and a prescription does not change that.
Facts on this page reflect Good Girl Rx's own public disclosures when we last checked them, in August 2026. Prices and terms change without notice — confirm on Good Girl Rx's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved, and growth-hormone secretagogues are banned in tested sport year-round. See our disclosure and editorial policy.